Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 2/20 | 0.43 |
| ▸ | PRKCA | P17252 | 2/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.37 |
| ▸ | PRKCH | P24723 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.37 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17656222 | 0.85 | DRD2 (0.39) | DRD2DRD4ACE | |
| SCHEMBL10274326 | 0.85 | DRD2 (0.39) | DRD2DRD4ACE | |
| SCHEMBL13006634 | 0.81 | LMNA (0.40) | DRD2DRD4ACE | |
| SCHEMBL23761367 | 0.77 | PRKCD (0.49) | PRKCGPRKCAPRKCDDRD2DRD4 | |
| SCHEMBL6099395 | 0.77 | PRKCD (0.49) | PRKCGPRKCAPRKCDDRD2DRD4 | |
| SCHEMBL7823659 | 0.77 | PRKCD (0.49) | PRKCGPRKCAPRKCDDRD2DRD4 | |
| SCHEMBL11395616 | 0.77 | MTNR1A (0.37) | ACE | |
| SCHEMBL26724341 | 0.76 | NOTUM (0.40) | ACENOTUM | |
| SCHEMBL26729559 | 0.76 | ACE (0.40) | ACE | |
| SCHEMBL13831608 | 0.75 | NOTUM (0.50) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2861581-B9 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2861581-B1 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-02-01 | — | — | EP | disclosed |